AccuStem Sciences, Inc. Announces Chairman Purchase of Shares
AccuStem Sciences (OTCQB: ACUT) announced that its Chairman, Gabriele Cerrone, has acquired an additional 24,500 shares, bringing his total ownership to 3,855,723 shares.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
AccuStem Sciences (OTCQB: ACUT) announced that its Chairman, Gabriele Cerrone, has acquired an additional 24,500 shares, bringing his total ownership to 3,855,723 shares. This purchase reflects the Chairman's confidence in the company’s future, as AccuStem focuses on developing innovative molecular testing for cancer diagnostics aimed at improving patient outcomes. The company is dedicated to addressing critical clinical needs throughout cancer screening, treatment, and monitoring.
Positive
- Chairman Gabriele Cerrone increased his stake in the company by purchasing 24,500 shares, a sign of confidence in ACUT's future.
- Total shares held by Cerrone now stand at 3,855,723, indicating strong insider commitment.
Negative
- None.
Details
News Market Reaction – ACUT
The recorded move for ACUT in the trading session of this news was -13.99%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
LONDON and PHOENIX, Nov. 22, 2022 (GLOBE NEWSWIRE) -- AccuStem Sciences, Inc. (OTCQB: ACUT), a clinical stage diagnostics company dedicated to improving outcomes for patients with cancer, announced that its Chairman of the Board, Mr. Gabriele Cerrone, has notified the Company that he has recently purchased an additional 24,500 ACUT shares in the open market. This brings his total holding to 3,855,723 shares.
About AccuStem
AccuStem is a clinical stage diagnostics company dedicated to optimizing outcomes and quality of life for all patients with cancer. We plan to drive innovation in healthcare by offering proprietary molecular testing that addresses unmet clinical needs from cancer screening through treatment and monitoring. By interrogating novel disease pathways, such as tumor “stemness,” we believe our tools will help care teams better understand the biology of each patient’s cancer, leading to more informed decision making. For more information, please visit www.accustem.com.
Media Contact:
Jeff Fensterer
Phone: 415-640-6010
Email: jeff@accustem.com
Investor Contact:
Wendy Blosser
Email: investors@accustem.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.